CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $576.3M, above the global median of $520.53M
- PositionDebt-to-equity is 1.23×, higher than 95% of its Medical Devices peers (median 0.11×)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
817.04MUSDvs all stocks (USD)
Trailing P/E
29.30xvs Medical Devices peers
Revenue (TTM)
576.30MUSDvs all stocks (USD)
Profit Margin
4.94%vs Medical Devices peers
Beta
0.6530xvs all stocks
52-Week Change
91.43%vs all stocks
Market Capitalization
817.04MUSDvs all stocks (USD)
Enterprise Value
1.14BUSDvs all stocks (USD)
Trailing P/E
29.30xvs Medical Devices peers
Forward P/E
13.23xvs Medical Devices peers
PEG Ratio
-0.1302xvs Medical Devices peers
Price to Sales (TTM)
1.41xvs Medical Devices peers
Price to Book (MRQ)
4.30xvs Medical Devices peers
Enterprise to Revenue
1.98xvs Medical Devices peers
Enterprise to EBITDA
14.09xvs Medical Devices peers
Gross Margin
68.72%vs Medical Devices peers
Profit Margin
4.94%vs Medical Devices peers
Operating Margin
6.73%vs Medical Devices peers
Return on Assets (TTM)
5.61%vs Medical Devices peers
Return on Equity (TTM)
16.46%vs Medical Devices peers
Revenue (TTM)
576.30MUSDvs all stocks (USD)
Revenue per Share (TTM)
8.61USDUpdated Jul 18, 2026Quarterly Revenue Growth
6.60%vs Medical Devices peers
Gross Profit (TTM)
395.87MUSDvs all stocks (USD)
EBITDA (TTM)
106.31MUSDvs all stocks (USD)
Net Income (TTM)
28.48MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
6.63%vs Medical Devices peers
Operating Cash Flow (TTM)
102.94MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
63.31MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Minority Interest (Equity)
44.34MUSDFY2025 · Dec 31, 2025Revenue
568.09MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
179.93MUSDFY2025 · Dec 31, 2025Gross Profit
388.16MUSDFY2025 · Dec 31, 2025Operating Income
56.29MUSDvs all stocks (USD)
Pre-tax Income
25.71MUSDFY2025 · Dec 31, 2025Income Tax Expense
-1.56MUSDFY2025 · Dec 31, 2025Net Income
27.27MUSDFY2025 · Dec 31, 2025EBIT
52.20MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
101.85MUSDFY2025 · Dec 31, 2025Research & Development
12.11MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
314.03MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
26.49MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
27.27MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
-4.54MUSDFY2025 · Dec 31, 2025Operating Cash Flow
93.18MUSDFY2025 · Dec 31, 2025Free Cash Flow
90.62MUSDDerived from operating cash flow minus capital expenditure. This filing charges 47.01M of depreciation against 2.56M of capital expenditure, and its own free-cash-flow line reads 72.11M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
51.24MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
27.27MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
47.01MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-909.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.67MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.16MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-916.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
6.89MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.56MUSDFY2025 · Dec 31, 2025Net Acquisitions
-686.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.25MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
76.91MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-119.82MUSDFY2025 · Dec 31, 2025Other Financing Charges
-21.30MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-62.14MUSDFY2025 · Dec 31, 2025Shares Outstanding
67.64MSharesUpdated Jul 18, 2026Float Shares
33.31MSharesUpdated Jul 18, 2026Shares Short
2.18MSharesUpdated Jul 18, 2026Short Ratio
3.11daysvs all stocks
Short % of Shares Outstanding
4.71%vs all stocks
% Held by Insiders
11.75%vs all stocks
% Held by Institutions
78.33%vs all stocks
Total Cash (MRQ)
35.85MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.5290USDUpdated Jul 18, 2026Total Debt (MRQ)
288.42MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.23xvs Medical Devices peers
Current Ratio (MRQ)
1.69xvs Medical Devices peers
Book Value per Share (MRQ)
2.79USDUpdated Jul 18, 2026Total Assets
683.56MUSDvs all stocks (USD)
Total Current Assets
272.84MUSDFY2025 · Dec 31, 2025Total Liabilities
455.11MUSDFY2025 · Dec 31, 2025Total Non-current Assets
410.72MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
294.73MUSDFY2025 · Dec 31, 2025Total Current Liabilities
160.38MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
51.24MUSDFY2025 · Dec 31, 2025Accounts Receivable
128.30MUSDFY2025 · Dec 31, 2025Inventory
82.24MUSDFY2025 · Dec 31, 2025Accounts Payable
10.93MUSDFY2025 · Dec 31, 2025Short-term Debt
15.00MUSDFY2025 · Dec 31, 2025Other Current Liabilities
21.06MUSDFY2025 · Dec 31, 2025Long-term Debt
278.95MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
15.35MUSDFY2025 · Dec 31, 2025Common Stock (Book)
83.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-334.93MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
228.45MUSDvs all stocks (USD)
52-Week Low
5.81USDUpdated Jul 18, 202652-Week High
12.53USDUpdated Jul 18, 202652-Week Change
91.43%vs all stocks
Beta
0.6530xvs all stocks
50-Day MA
9.93USDUpdated Jul 18, 2026200-Day MA
8.52USDUpdated Jul 18, 2026Avg 10-Day Volume
718.59KSharesUpdated Jul 18, 2026Avg 30-Day Volume
665.40KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
0.4100USDUpdated Jul 18, 2026Other Income / Expense
-4.10MUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Intangible Concentration
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
How does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 1.23×, higher than 95% of its Medical Devices peers (median 0.11×)Significant
Debt-to-equity: 1.23Industry median: 0.11Industry P95: 1.20Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.69Profit Margin: 0.05
Financial Health
Altman Z-Score 1.67: grey zoneSignificant
Altman Z-Score: 1.67
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $576.3M, above the global median of $520.53MNotable
Revenue (USD): 576,300,032Global Median: 520,528,949.311
Levered free cash flow is $63.31M, above the global median of $16.24MNotable
Levered free cash flow (USD): 63,310,876Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Chengda Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Esperion Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Konruns Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen YHLO Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Chunlizhengda Medical Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
HK inno.N Corporation
Tier 1ProductionApproval-Gated PipelineRule
Gansu Longshenrongfa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Anglikang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Center Laboratories, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanxi Zhendong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Avalon Technologies Ltd.
2 interpretationsIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Pearl Global Industries Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
XPEL, Inc.
3 interpretationsFCF Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated